We have taken 60 years to discover that a key treatment against diabetes does not work as we thought
The drugs may well be the substance that we study the most before getting the market: preclinical and clinical trials; experiments In vitroin animals and in people … everything to make sure the treatment is safe and works. But sometimes the question is another: because works. Because the answer can be so complex that we are late for decades to unravel it at all. Also in the brain. Something like that It has happened with metformina compound used for more than six decades in the treatment of diabetes: a new study has found that This drug It acts in our brain and not only in the liver as we believed before. The discovery opens the door to possible new therapeutic, more effective and precise pathways, in the treatment of diabetes. Rap1. The new study develops around Rap1 proteina protein that is usually found in the brain region known as ventromedial hypothalamus (VMH). As the team observed in its analysis, metformin acts in this region “turn off” the rap1 function. Modified mice. To check it, the team administered a high fat diet, with which they emulated the effects of type 2 diabetes, to modified mice so that they did not have the rap1 protein in their VMH. Then they administered several types of drugs against diabetes: metformin, insulin and GLP-1 agonists (peptide similar to glucagon 1). When this protein disappeared, metformin ceased to be effective in reducing blood sugar while the other treatments continued to work. The team performed another test to demonstrate the key role of the brain in the functioning of metformin. For this they inject small amounts of the drug diréctorly into the brains of mice with diabetes. They were able to observe that, in doing their blood sugar levels, they decreased, even with “thousands of times smaller” doses of which they are usually administered orally. Combined action. The new study suggests that the biochemical mechanisms with which metformin acts in our body are more complex than we thought. Until now we knew that the drug acted on the liver and we also had evidence that the intestines also act. Now we not only have evidence that it acts on the brain, but it seems that in this context it responds to smaller doses than is required to act in the other areas of the body. The details of the study have been published In an article In the magazine Science Advances. New treatments. The responsible team keeps the hope that the new discovery will contribute to the development of new treatments against diabetes, drugs that focus on this “path” of the brain. The effects of this drug go beyond the control of diabetes, the team recalls: it has also been linked to slower cerebral aging. Of course, it can also have adverse effects, although uncommon, one of the most serious is lactic acidosis, a serious and potentially deadly disease. In Xataka | This is the great hope of competition to replace Ozempic. Your weapon: banish needles with a pill Image | Sweet Life
